Rash from chikungunya on the right foot
|Classification and external resources|
Chikungunya is an infection caused by the chikungunya virus. Symptoms include the fever and joint pain. These typically occurs two to twelve days after exposure. Other symptoms may include headache, muscle pain, joint swelling, and a rash. Most people are better within a week; however, occasionally the join pain may last for months. The risk of death is a around 1 in 1,000. The very young, old, and those with other health problems are at risk of more severe disease.
The virus is spread between people by two types of mosquitos: Aedes albopictus and Aedes aegypti. They mainly bite during the day. The virus may circulate within a number of animals including birds and rodents. Diagnosis is by either testing the blood for the viruses RNA or antibodies to the virus. The symptoms can be mistaken for those of dengue fever and Zika fever. After a single infection it is believed most people become immune.
The best means of prevention is overall mosquito control and the avoidance of bites in areas where the disease is common. This may be partly achieved by decreases mosquitoes access to water and with the use of insect repellent and mosquito nets. There is no vaccine and no specific treatment as of 2016. Recommendations include rest, fluids, and medications to help with fever and joint pain.
While the disease typically occurs in Africa and Asia, outbreaks have been reported in Europe and the Americas since the 2000s. In 2014 more than a million suspected cases occurred. In 2014 it was occurring in Florida in the continental United States but as of 2016 there was no further locally acquired cases. The disease was first identified in 1952 in Tanzania. The term is from the Kimakonde language and means "to become contorted".
Signs and symptoms
The incubation period of the chikungunya virus ranges from one to twelve days, and is most typically three to seven. The disease may be asymptomatic, but generally is not, as 72% to 97% of those infected will develop symptoms. Characteristic symptoms include sudden onset with high fever, joint pain, and rash. Other symptoms may occur, including headache, fatigue, digestive complaints, and conjunctivitis.
Information gained during recent epidemics suggests that chikungunya fever may result in a chronic phase as well as the phase of acute illness. Within the acute phase, two stages have been identified: a viral stage during the first five to seven days, during which viremia occurs, followed by a convalescent stage lasting approximately ten days, during which symptoms improve and the virus cannot be detected in the blood. Typically, the disease begins with a sudden high fever that lasts from a few days to a week, and sometimes up to ten days. The fever is usually above 39 °C (102 °F) and sometimes reaching 40 °C (104 °F) and may be biphasic—lasting several days, breaking, and then returning. Fever occurs with the onset of viremia, and the level of virus in the blood correlates with the intensity of symptoms in the acute phase. When IgM, an antibody that is a response to the initial exposure to an antigen, appears in the blood, viremia begins to diminish. However, headache, insomnia and an extreme degree of exhaustion remain, usually about five to seven days.
Following the fever, strong joint pain or stiffness occurs; it usually lasts weeks or months, but may last for years. The joint pain can be debilitating, often resulting in near immobility of the affected joints. Joint pain is reported in 87–98% of cases, and nearly always occurs in more than one joint, though joint swelling is uncommon. Typically the affected joints are located in both arms and legs, and are affected symmetrically. Joints are more likely to be affected if they have previously been damaged by disorders such as arthritis. Pain most commonly occurs in peripheral joints, such as the wrists, ankles, and joints of the hands and feet as well as some of the larger joints, typically the shoulders, elbows and knees. Pain may also occur in the muscles or ligaments.
Rash occurs in 40-50% of cases, generally as a maculopapular rash occurring two to five days after onset of symptoms. Digestive symptoms, including abdominal pain, nausea, vomiting or diarrhea, may also occur. In more than half of cases, normal activity is limited by significant fatigue and pain. Infrequently, inflammation of the eyes may occur in the form of iridocyclitis, or uveitis, and retinal lesions may occur.
Rarely, neurological disorders have been reported in association with chikungunya virus, including Guillain–Barré syndrome, palsies, meningoencephalitis, flaccid paralysis and neuropathy. In contrast to dengue fever, Chikungunya fever very rarely causes hemorrhagic complications. Symptoms of bleeding should lead to consideration of alternative diagnoses or co-infection with dengue fever or coexisting congestive hepatopathy.
Observations during recent epidemics have suggested chikungunya may cause long-term symptoms following acute infection. This condition has been termed chronic chikungunya virus-induced arthralgia. Long-term symptoms are not an entirely new observation; long-term arthritis was observed following an outbreak in 1979. Common predictors of prolonged symptoms are increased age and prior rheumatological disease.
During the La Reunion outbreak in 2006, more than 50% of subjects over the age of 45 reported long-term musculoskeletal pain with up to 60% of people reporting prolonged painful joints three years following initial infection. A study of imported cases in France reported that 59% of people still suffered from arthralgia two years after acute infection. Following a local epidemic of chikungunya in Italy, 66% of people reported muscle pains, joint pains, or asthenia at one year after acute infection.
Currently, the cause of these chronic symptoms is not fully known. Markers of autoimmune or rheumatoid disease have not been found in people reporting chronic symptoms. However, some evidence from humans and animal models suggests chikungunya may be able to establish chronic infections within the host. Viral antigen was detected in a muscle biopsy of a person suffering a recurrent episode of disease three months after initial onset. Additionally, viral antigen and viral RNA were found in macrophages in the synovial joint of a person experiencing a relapse of musculoskeletal disease 18 months after initial infection. Several animal models have also suggested chikungunya virus may establish persistent infections. In a mouse model, viral RNA was detected specifically in joint-associated tissue for at least 16 weeks after inoculation, and was associated with chronic synovitis. Similarly, another study reported detection of a viral reporter gene in joint tissue of mice for weeks after inoculation. In a nonhuman primate model, chikungunya virus was found to persist in the spleen for at least six weeks.
|Cryoelectron microscopy reconstruction of chikungunya virus. From EMDB entry |
|Group:||Group IV ((+)ssRNA)|
Chikungunya virus, also referred to as CHIKV, is a member of the alphavirus genus, and Togaviridae family. It is an RNA virus with a positive-sense single-stranded genome of about 11.6kb. It is a member of the Semliki Forest virus complex and is closely related to Ross River virus, O'nyong'nyong virus, and Semliki Forest virus. Because it is transmitted by arthropods, namely mosquitoes, it can also be referred to as an arbovirus (arthropod-borne virus). In the United States, it is classified as a category C priority pathogen, and work requires biosafety level III precautions.
Chikungunya is generally transmitted from mosquitoes to humans. Less common modes of transmission include vertical transmission, which is transmission from mother to child during pregnancy or at birth. Transmission via infected blood products and through organ donation is also theoretically possible during times of outbreak, though no cases have yet been documented.
Chikungunya is related to mosquitoes, their environments, and human behavior. The adaptation of mosquitoes to the changing climate of North Africa around 5,000 years ago made them seek out environments where humans stored water. Human habitation and the mosquitoes’ environments were then very closely connected. During periods of epidemics humans are the reservoir of the virus. Because high amounts of virus are present in the blood in the beginning of acute infection, the virus can be spread from a viremic human to a mosquito, and back to a human. During other times, monkeys, birds and other vertebrates have served as reservoirs. Three genotypes of this virus have been described, each with a distinct genotype and antigenic character: West African, East/Central/South African, and Asian genotypes.
Chikungunya is spread through bites from Aedes mosquitoes, and the species A. aegypti was identified as the most common vector, though the virus has recently been associated with many other species, including A. albopictus. Research by the Pasteur Institute in Paris has suggested chikungunya virus strains in the 2005-2006 Reunion Island outbreak incurred a mutation that facilitated transmission by the Asian tiger mosquito (A. albopictus). Other species potentially able to transmit the chikungunya virus include Ae. furcifer-taylori, Ae. africanus, and Ae. luteocephalus.
The chikungunya virus is passed to humans when a bite from an infected mosquito breaks the skin and introduces the virus into the body. The pathogenesis of chikungunya infection in humans is still poorly understood, despite recent outbreaks. It appears that in vitro, chikungunya virus is able to replicate in human epithelial and endothelial cells, primary fibroblasts, and monocyte-derived macrophages. Viral replication is highly cytopathic, but susceptible to type-I and -II interferon. In vivo, in studies using living cells, chikungunya virus appears to replicate in fibroblasts, skeletal muscle progenitor cells, and myofibers.
The type-1 interferon response seems to play an important role in the host's response to chikungunya infection. Upon infection with chikungunya, the host's fibroblasts produce type-1 alpha and beta interferon (IFN-α and IFN-β). In mouse studies, deficiencies in INF-1 in mice exposed to the virus cause increased morbidity and mortality. The chikungunya-specific upstream components of the type-1 interferon pathway involved in the host's response to chikungunya infection are still unknown. Nonetheless, mouse studies suggest that IPS-1 is an important factor, and that IRF3 and IRF7 are important in an age-dependent manner. Mouse studies also suggest that chikungunya evades host defenses and counters the type-I interferon response by producing NS2, a nonstructural protein that degrades RBP1 and turns off the host cell's ability to transcribe DNA. NS2 interferes with the JAK-STAT signaling pathway and prevents STAT from becoming phosphorylated.
In the acute phase of chikungunya, the virus is typically present in the areas where symptoms present, specifically skeletal muscles, and joints. In the chronic phase, it is suggested that viral persistence (the inability of the body to entirely rid itself of the virus), lack of clearance of the antigen, or both, contribute to joint pain. The inflammation response during both the acute and chronic phase of the disease results in part from interactions between the virus and monocytes and macrophages. Chikungunya virus disease in humans is associated with elevated serum levels of specific cytokines and chemokines. High levels of specific cytokines have been linked to more severe acute disease: interleukin-6 (IL-6), IL-1β, RANTES, monocyte chemoattractant protein 1 (MCP-1), monokine induced by gamma interferon (MIG), and interferon gamma-induced protein 10 (IP-10). Cytokines may also contribute to chronic chikungunya virus disease, as persistent joint pain has been associated with elevated levels of IL-6 and granulocyte-macrophage colony-stimulating factor (GM-CSF). In those with chronic symptoms, a mild elevation of C-reactive protein (CRP) has been observed, suggesting ongoing chronic inflammation. However, there is little evidence linking chronic chikungunya virus disease and the development of autoimmunity.
The virus consists of four nonstructural proteins and three structural proteins. The structural proteins are the capsid and two envelope glycoproteins: E1 and E2, which form heterodimeric spikes on the viron surface. E2 binds to cellular receptors in order to enter the host cell through receptor-mediated endocytosis. E1 contains a fusion peptide which, when exposed to the acidity of the endosome in eukaryotic cells, dissociates from E2 and initiates membrane fusion that allows the release of nucleocapsids into the host cytoplasm, promoting infection. The mature virion contains 240 heterodimeric spikes of E2/E1, which after release, bud on the surface of the infected cell, where they are released by exocytosis to infect other cells.
Chikungunya is diagnosed on the basis of clinical, epidemiological, and laboratory criteria. Clinically, acute onset of high fever and severe joint pain would lead to suspicion of chikungunya. Epidemiological criteria consist of whether the individual has traveled to or spent time in an area in which chikungunya is present within the last twelve days (i.e. the potential incubation period). Laboratory criteria include a decreased lymphocyte count consistent with viremia. However a definitive laboratory diagnosis can be accomplished through viral isolation, RT-PCR, or serological diagnosis.
The differential diagnosis may include infection with other mosquito-borne viruses, such as dengue or malaria, and infection with influenza. Chronic recurrent polyarthralgia occurs in at least 20% of chikungunya patients one year after infection, whereas such symptoms are uncommon in dengue.
Virus isolation provides the most definitive diagnosis, but takes one to two weeks for completion and must be carried out in biosafety level III laboratories. The technique involves exposing specific cell lines to samples from whole blood and identifying chikungunya virus-specific responses. RT-PCR using nested primer pairs is used to amplify several chikungunya-specific genes from whole blood, generating thousands to millions of copies of the genes in order to identify them. RT-PCR can also be used to quantify the viral load in the blood. Using RT-PCR, diagnostic results can be available in one to two days. Serological diagnosis requires a larger amount of blood than the other methods, and uses an ELISA assay to measure chikungunya-specific IgM levels in the blood serum. One advantage offered by serological diagnosis is that serum IgM is detectable from 5 days to months after the onset of symptoms, but drawbacks are that results may require two to three days, and false positives can occur with infection due to other related viruses, such as o'nyong'nyong virus and Semliki Forest virus.
Presently, there is no specific way to test for chronic signs and symptoms associated with Chikungunya fever although nonspecific laboratory findings such as C reactive protein and elevated cytokines can correlate with disease activity.
Because no approved vaccine exists, the most effective means of prevention are protection against contact with the disease-carrying mosquitoes and controlling mosquito populations by limiting their habitat. Mosquito control focuses on eliminating the standing water where mosquitos lay eggs and develop as larva; if elimination of the standing water is not possible, insecticides or biological control agents can be added. Methods of protection against contact with mosquitos include using insect repellents with substances such as DEET, icaridin, PMD (p-menthane-3,8-diol, a substance derived from the lemon eucalyptus tree), or IR3535. However, increasing insecticide resistance presents a challenge to chemical control methods.
Wearing bite-proof long sleeves and trousers also offers protection, and garments can be treated with pyrethroids, a class of insecticides that often has repellent properties. Vaporized pyrethroids (for example in mosquito coils) are also insect repellents. As infected mosquitos often feed and rest inside homes, securing screens on windows and doors will help to keep mosquitoes out of the house. In the case of the day-active A. aegypti and A. albopictus, however, this will have only a limited effect, since many contacts between the mosquitoes and humans occur outdoors.
Currently, no approved vaccines are available. A phase-II vaccine trial used a live, attenuated virus, to develop viral resistance in 98% of those tested after 28 days and 85% still showed resistance after one year. However, 8% of people reported transient joint pain, and attenuation was found to be due to only two mutations in the E2 glycoprotein. Alternative vaccine strategies have been developed, and show efficacy in mouse models. In August 2014 researchers at the National Institute of Allergy and Infectious Diseases in the USA were testing an experimental vaccine which uses virus-like particles (VLPs) instead of attenuated virus. All the 25 people participated in this phase 1 trial developed strong immune responses. Phase 2 trial will commence using 400 adults aged 18 to 60 and take place at 6 locations in the Caribbean. Even with a vaccine, mosquito population control and bite prevention will be necessary to control chikungunya disease.
Currently, no specific treatment for chikungunya is available. Supportive care is recommended, and symptomatic treatment of fever and joint swelling includes the use of nonsteroidal anti-inflammatory drugs such as naproxen, non-aspirin analgesics such as paracetamol (acetaminophen) and fluids. Aspirin is not recommended due to the increased risk of bleeding. Despite anti-inflammatory effects, corticosteroids are not recommended during the acute phase of disease, as they may cause immunosuppression and worsen infection.
Passive immunotherapy has potential benefit in treatment of chikungunya. Studies in animals using passive immunotherapy have been effective, and clinical studies using passive immunotherapy in those particularly vulnerable to severe infection are currently in progress. Passive immunotherapy involves administration of anti-CHIKV hyperimmune human intravenous antibodies (immunoglobulins) to those exposed to a high risk of chikungunya infection. No antiviral treatment for chikungunya virus is currently available, though testing has shown several medications to be effective in vitro.
In those who have more than two weeks of arthritis, ribavirin may be useful. The effect of chloroquine is not clear. It does not appear to help acute disease, but tentative evidence indicates it might help those with chronic arthritis. Steroids do not appear to be an effective treatment. NSAIDs and simple analgesics can be used to provide partial symptom relief in most cases. Methotrexate, a drug used in the treatment of rheumatoid arthritis, has been shown to have benefit in treating inflammatory polyarthritis resulting from chikungunya, though the drug mechanism for improving viral arthritis is unclear.
The mortality rate of chikungunya is slightly less than 1 in 1000. Those over the age of 65, neonates, and those with underlying chronic medical problems are most likely to have severe complications. Neonates are vulnerable as it is possible to vertically transmit chikungunya from mother to infant during delivery, which results in high rates of morbidity, as infants lack fully developed immune systems. The likelihood of prolonged symptoms or chronic joint pain is increased with increased age and prior rheumatological disease.
Historically, chikungunya has been present mostly in the developing world. The disease causes an estimated 3 million infections each year. Epidemics in the Indian Ocean, Pacific Islands, and in the Americas, continue to change the distribution of the disease. In Africa, chikungunya is spread by a sylvatic cycle in which the virus largely cycles between other non-human primates, small mammals, and mosquitos between human outbreaks. During outbreaks, due to the high concentration of virus in the blood of those in the acute phase of infection, the virus can circulate from humans to mosquitoes and back to humans. The transmission of the pathogen between humans and mosquitoes that exist in urban environments was established on multiple occasions from strains occurring on the eastern half of Africa in non-human primate hosts. This emergence and spread beyond Africa may have started as early as the 18th century. Currently, available data does not indicate whether the introduction of chikungunya into Asia occurred in the 19th century or more recently, but this epidemic Asian strain causes outbreaks in India and continues to circulate in Southeast Asia. In Africa, outbreaks were typically tied to heavy rainfall causing increased mosquito population. In recent outbreaks in urban centers, the virus has spread by circulating between humans and mosquitoes.
Global rates of chikungunya infection are variable, depending on outbreaks. When chikungunya was first identified in 1952, it had a low-level circulation in West Africa, with infection rates linked to rainfall. Beginning in the 1960s, periodic outbreaks were documented in Asia and Africa. However, since 2005, following several decades of relative inactivity, chikungunya has re-emerged and caused large outbreaks in Africa, Asia, and the Americas. In India, for instance, chikungunya re-appeared following 32 years of absence of viral activity. Outbreaks have occurred in Europe, the Caribbean, and South America, areas in which chikungunya was not previously transmitted. Local transmission has also occurred in the United States and Australia, countries in which the virus was previously unknown. In 2005, an outbreak on the island of Réunion was the largest then documented, with an estimated 266,000 cases on an island with a population of approximately 770,000. In a 2006 outbreak, India reported 1.25 million suspected cases. Chikungunya was recently introduced to the Americas, and from 2013-14 in the Americas, 1,118,763 suspected cases and 24,682 confirmed cases were reported by the PAHO.
An analysis of the chikungunya virus's genetic code suggests that the increased severity of the 2005–present outbreak may be due to a change in the genetic sequence which altered the E1 segment of the virus' viral coat protein, a variant called E1-A226V. This mutation potentially allows the virus to multiply more easily in mosquito cells. The change allows the virus to use the Asian tiger mosquito (an invasive species) as a vector in addition to the more strictly tropical main vector, Aedes aegypti. Enhanced transmission of chikungunya virus by A. albopictus could mean an increased risk for outbreaks in other areas where the Asian tiger mosquito is present. A albopictus is an invasive species which has spread through Europe, the Americas, the Caribbean, Africa and the Middle East.
After the detection of zika virus in Brazil in April 2015, the first ever in the Western Hemisphere, it is now thought some chikungunya and dengue cases could in fact be zika virus cases or coinfections.
The word 'chikungunya' is believed to have been derived from a description in the Makonde language, meaning "that which bends up", of the contorted posture of people affected with the severe joint pain and arthritic symptoms associated with this disease. The disease was first described by Marion Robinson and W.H.R. Lumsden in 1955, following an outbreak in 1952 on the Makonde Plateau, along the border between Mozambique and Tanganyika (the mainland part of modern-day Tanzania).
According to the initial 1955 report about the epidemiology of the disease, the term 'chikungunya' is derived from the Makonde root verb kungunyala, meaning to dry up or become contorted. In concurrent research, Robinson glossed the Makonde term more specifically as "that which bends up". Subsequent authors apparently overlooked the references to the Makonde language and assumed the term to have been derived from Swahili, the lingua franca of the region. The erroneous attribution to Swahili has been repeated in numerous print sources. Many erroneous spellings of the name of the disease are also in common use.
Since its discovery in Tanganyika, Africa, in 1952, chikungunya virus outbreaks have occurred occasionally in Africa, South Asia, and Southeast Asia, but recent outbreaks have spread the disease over a wider range.
- "chikungunya". Oxford Learner's Dictionary. Oxford University Press. Retrieved 4 November 2014.
- "Chikungunya Fact sheet". WHO. April 2016. Retrieved 26 September 2016.
- "Chikungunya Virus Symptoms, Diagnosis, & Treatment". CDC. 6 April 2016. Retrieved 26 September 2016.
- Caglioti, C; Lalle, E; Castilletti, C; Carletti, F; Capobianchi, MR; Bordi, L (July 2013). "Chikungunya virus infection: an overview.". The new microbiologica. 36 (3): 211–27. PMID 23912863.
- "Prevention". CDC. 26 February 2016. Retrieved 26 September 2016.
- Staples JE, Fischer M (2014). "Chikungunya virus in the Americas--what a vectorborne pathogen can do". N. Engl. J. Med. 371 (10): 887–9. doi:10.1056/NEJMp1407698. PMID 25184860.
- "2016 provisional data for the United States". CDC. 20 September 2016. Retrieved 26 September 2016.
- Thiberville, Simon-Djamel; Moyen, Nanikaly; Dupuis-Maguiraga, Laurence; Nougairede, Antoine; Gould, Ernest A.; Roques, Pierre; de Lamballerie, Xavier (2013). "Chikungunya fever: Epidemiology, clinical syndrome, pathogenesis and therapy". Antiviral Research. 99 (3): 345–370. doi:10.1016/j.antiviral.2013.06.009. ISSN 0166-3542.
- Powers AM, Logue CH (September 2007). "Changing patterns of chikungunya virus: re-emergence of a zoonotic arbovirus". J. Gen. Virol. 88 (Pt 9): 2363–77. doi:10.1099/vir.0.82858-0. PMID 17698645.
- Burt, Felicity J; Rolph, Micheal S; Rulli, Nestor E; Mahalingam, Suresh; Heise, Mark T (2012). "Chikungunya: a re-emerging virus". The Lancet. 379 (9816): 662–671. doi:10.1016/S0140-6736(11)60281-X. ISSN 0140-6736. PMID 22100854.
- Weaver, Scott C.; Lecuit, Marc (2015). "Chikungunya Virus and the Global Spread of a Mosquito-Borne Disease". New England Journal of Medicine. 372 (13): 1231–1239. doi:10.1056/NEJMra1406035. ISSN 0028-4793.
- Chhabra M, Mittal V, Bhattacharya D, Rana U, Lal S (2008). "Chikungunya fever: a re-emerging viral infection". Indian J Med Microbiol. 26 (1): 5–12. doi:10.4103/0255-0857.38850. PMID 18227590.
- Capeding, MR; Chua, MN; Hadinegoro, SR; Hussain, II; Nallusamy, R; Pitisuttithum, P; Rusmil, K; Thisyakorn, U; Thomas, SJ; Huu Tran, N; Wirawan, DN; Yoon, IK; Bouckenooghe, A; Hutagalung, Y; Laot, T; Wartel, TA (2013). "Dengue and other common causes of acute febrile illness in Asia: an active surveillance study in children.". PLoS neglected tropical diseases. 7 (7): e2331. doi:10.1371/journal.pntd.0002331. PMID 23936565.
- Powers, Ann. "Chikungunya". CDC. Retrieved 12 May 2014.
- Mahendradas P, Ranganna SK, Shetty R, Balu R, Narayana KM, Babu RB, Shetty BK (February 2008). "Ocular manifestations associated with chikungunya". Ophthalmology. 115 (2): 287–91. doi:10.1016/j.ophtha.2007.03.085. PMID 17631967.
- MacFadden, D. R.; Bogoch, I. I. (2014). "Chikungunya". Canadian Medical Association Journal. 186 (10): 775–775. doi:10.1503/cmaj.140031. ISSN 0820-3946.
- Parashar, Deepti; Cherian, Sarah (2014). "Antiviral Perspectives for Chikungunya Virus". BioMed Research International. 2014: 1–11. doi:10.1155/2014/631642. ISSN 2314-6133.
- Munoz-Zanzi, Claudia; Javelle, Emilie; Ribera, Anne; Degasne, Isabelle; Gaüzère, Bernard-Alex; Marimoutou, Catherine; Simon, Fabrice (2015). "Specific Management of Post-Chikungunya Rheumatic Disorders: A Retrospective Study of 159 Cases in Reunion Island from 2006-2012". PLOS Neglected Tropical Diseases. 9 (3): e0003603. doi:10.1371/journal.pntd.0003603. ISSN 1935-2735.
- Fourie ED, Morrison JG (28 July 1979). "Rheumatoid arthritic syndrome after chikungunya fever.". South African medical [Suid-Afrikaanse tydskrif vir geneeskunde]. 56 (4): 130–2. PMID 494034.
- Schilte C, Staikowsky F, Staikovsky F, Couderc T, Madec Y, Carpentier F, Kassab S, Albert ML, Lecuit M, Michault A (2013). "Chikungunya virus-associated long-term arthralgia: a 36-month prospective longitudinal study.". PLoS neglected tropical diseases. 7 (3): e2137. doi:10.1371/journal.pntd.0002137. PMID 23556021.
- Gérardin P, Fianu A, Michault A, Mussard C, Boussaïd K, Rollot O, Grivard P, Kassab S, Bouquillard E, Borgherini G, Gaüzère BA, Malvy D, Bréart G, Favier F (9 January 2013). "Predictors of Chikungunya rheumatism: a prognostic survey ancillary to the TELECHIK cohort study.". Arthritis Research & Therapy. 15 (1): R9. doi:10.1186/ar4137. PMID 23302155.
- Moro ML, Grilli E, Corvetta A, Silvi G, Angelini R, Mascella F, Miserocchi F, Sambo P, Finarelli AC, Sambri V, Gagliotti C, Massimiliani E, Mattivi A, Pierro AM, Macini P (August 2012). "Long-term chikungunya infection clinical manifestations after an outbreak in Italy: a prognostic cohort study.". The Journal of infection. 65 (2): 165–72. doi:10.1016/j.jinf.2012.04.005. PMID 22522292.
- Sissoko D, Malvy D, Ezzedine K, Renault P, Moscetti F, Ledrans M, Pierre V (2009). "Post-epidemic Chikungunya disease on Reunion Island: course of rheumatic manifestations and associated factors over a 15-month period.". PLoS neglected tropical diseases. 3 (3): e389. doi:10.1371/journal.pntd.0000389. PMID 19274071.
- Larrieu S, Pouderoux N, Pistone T, Filleul L, Receveur MC, Sissoko D, Ezzedine K, Malvy D (Jan 2010). "Factors associated with persistence of arthralgia among Chikungunya virus-infected travellers: report of 42 French cases.". Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology. 47 (1): 85–8. doi:10.1016/j.jcv.2009.11.014. PMID 20004145.
- Manimunda SP, Vijayachari P, Uppoor R, Sugunan AP, Singh SS, Rai SK, Sudeep AB, Muruganandam N, Chaitanya IK, Guruprasad DR (June 2010). "Clinical progression of chikungunya fever during acute and chronic arthritic stages and the changes in joint morphology as revealed by imaging.". Transactions of the Royal Society of Tropical Medicine and Hygiene. 104 (6): 392–9. doi:10.1016/j.trstmh.2010.01.011. PMID 20171708.
- Ozden S, Huerre M, Riviere JP, Coffey LL, Afonso PV, Mouly V, de Monredon J, Roger JC, El Amrani M, Yvin JL, Jaffar MC, Frenkiel MP, Sourisseau M, Schwartz O, Butler-Browne G, Desprès P, Gessain A, Ceccaldi PE (13 June 2007). "Human muscle satellite cells as targets of Chikungunya virus infection.". PLoS ONE. 2 (6): e527. doi:10.1371/journal.pone.0000527. PMID 17565380.
- Hoarau JJ, Jaffar Bandjee MC, Krejbich Trotot P, Das T, Li-Pat-Yuen G, Dassa B, Denizot M, Guichard E, Ribera A, Henni T, Tallet F, Moiton MP, Gauzère BA, Bruniquet S, Jaffar Bandjee Z, Morbidelli P, Martigny G, Jolivet M, Gay F, Grandadam M, Tolou H, Vieillard V, Debré P, Autran B, Gasque P (15 May 2010). "Persistent chronic inflammation and infection by Chikungunya arthritogenic alphavirus in spite of a robust host immune response.". Journal of immunology (Baltimore, Md. : 1950). 184 (10): 5914–27. doi:10.4049/jimmunol.0900255. PMID 20404278.
- Hawman DW, Stoermer KA, Montgomery SA, Pal P, Oko L, Diamond MS, Morrison TE (Dec 2013). "Chronic joint disease caused by persistent chikungunya virus infection is controlled by the adaptive immune response.". Journal of Virology. 87 (24): 13878–88. doi:10.1128/JVI.02666-13. PMID 24131709.
- Teo TH, Lum FM, Claser C, Lulla V, Lulla A, Merits A, Rénia L, Ng LF (1 January 2013). "A pathogenic role for CD4+ T cells during Chikungunya virus infection in mice.". Journal of immunology (Baltimore, Md. : 1950). 190 (1): 259–69. doi:10.4049/jimmunol.1202177. PMID 23209328.
- Labadie K, Larcher T, Joubert C, Mannioui A, Delache B, Brochard P, Guigand L, Dubreil L, Lebon P, Verrier B, de Lamballerie X, Suhrbier A, Cherel Y, Le Grand R, Roques P (March 2010). "Chikungunya disease in nonhuman primates involves long-term viral persistence in macrophages.". The Journal of Clinical Investigation. 120 (3): 894–906. doi:10.1172/JCI40104. PMID 20179353.
- Sun, S.; Xiang, Y.; Akahata, W.; Holdaway, H.; Pal, P.; Zhang, X.; Diamond, M. S.; Nabel, G. J.; Rossmann, M. G. (2013). "Structural analyses at pseudo atomic resolution of Chikungunya virus and antibodies show mechanisms of neutralization". ELife. 2: e00435. doi:10.7554/eLife.00435. PMC . PMID 23577234.
- Weaver, Scott C; Osorio, Jorge E; Livengood, Jill A; Chen, Rubing; Stinchcomb, Dan T (2012). "Chikungunya virus and prospects for a vaccine". Expert Review of Vaccines. 11 (9): 1087–1101. doi:10.1586/erv.12.84. ISSN 1476-0584.
- Powers AM, Brault AC, Shirako Y, Strauss EG, Kang W, Strauss JH, Weaver SC (November 2001). "Evolutionary relationships and systematics of the alphaviruses". Journal of Virology. 75 (21): 10118–31. doi:10.1128/JVI.75.21.10118-10131.2001. PMC . PMID 11581380.
- "NIAID Category A, B, and C Priority Pathogens". Retrieved 1 January 2014.
- "Biosafety in Microbiological and Biomedical Laboratories (BMBL) Fifth Edition" (PDF). Retrieved 1 January 2014.
- Morrison, T. E. (2014). "Reemergence of Chikungunya Virus". Journal of Virology. 88 (20): 11644–11647. doi:10.1128/JVI.01432-14. ISSN 0022-538X.
- Ng LC, Hapuarachchi HC (2010). "Tracing the path of Chikungunya virus--evolution and adaptation". Infect. Genet. Evol. 10 (7): 876–85. doi:10.1016/j.meegid.2010.07.012. PMID 20654736.
- Powers AM, Brault AC, Tesh RB, Weaver SC (February 2000). "Re-emergence of Chikungunya and O'nyong-nyong viruses: evidence for distinct geographical lineages and distant evolutionary relationships". J. Gen. Virol. 81 (Pt 2): 471–9. PMID 10644846.
- Enserink M (2007). "EPIDEMIOLOGY: Tropical Disease Follows Mosquitoes to Europe". Science. 317 (5844): 1485. doi:10.1126/science.317.5844.1485a. PMID 17872417.
- Sourisseau M, Schilte C, Casartelli N, Trouillet C, Guivel-Benhassine F, Rudnicka D, Sol-Foulon N, Le Roux K, Prevost MC, Fsihi H, Frenkiel MP, Blanchet F, Afonso PV, Ceccaldi PE, Ozden S, Gessain A, Schuffenecker I, Verhasselt B, Zamborlini A, Saïb A, Rey FA, Arenzana-Seisdedos F, Desprès P, Michault A, Albert ML, Schwartz O (June 2007). "Characterization of reemerging chikungunya virus.". PLoS Pathogens. 3 (6): e89. doi:10.1371/journal.ppat.0030089. PMC . PMID 17604450.
- Schilte C, Couderc T, Chretien F, Sourisseau M, Gangneux N, Guivel-Benhassine F, Kraxner A, Tschopp J, Higgs S, Michault A, Arenzana-Seisdedos F, Colonna M, Peduto L, Schwartz O, Lecuit M, Albert ML (15 February 2010). "Type I IFN controls chikungunya virus via its action on nonhematopoietic cells.". The Journal of Experimental Medicine. 207 (2): 429–42. doi:10.1084/jem.20090851. PMC . PMID 20123960.
- Rohatgi A, Corbo JC, Monte K, Higgs S, Vanlandingham DL, Kardon G, Lenschow DJ (11 December 2013). "Infection of myofibers contributes to the increased pathogenicity during infection with an epidemic strain of Chikungunya Virus.". Journal of Virology. 88 (5): 2414–25. doi:10.1128/JVI.02716-13. PMID 24335291.
- Schilte C, Couderc T, Chretien F, Sourisseau M, Gangneux N, Guivel-Benhassine F, Kraxner A, Tschopp J, Higgs S, Michault A, Arenzana-Seisdedos F, Colonna M, Peduto L, Schwartz O, Lecuit M, Albert ML (February 2010). "Type I IFN controls chikungunya virus via its action on nonhematopoietic cells". J. Exp. Med. 207 (2): 429–42. doi:10.1084/jem.20090851. PMC . PMID 20123960.
- Couderc T, Chrétien F, Schilte C, Disson O, Brigitte M, Guivel-Benhassine F, Touret Y, Barau G, Cayet N, Schuffenecker I, Desprès P, Arenzana-Seisdedos F, Michault A, Albert ML, Lecuit M (February 2008). "A mouse model for Chikungunya: young age and inefficient type-I interferon signaling are risk factors for severe disease". PLoS Pathog. 4 (2): e29. doi:10.1371/journal.ppat.0040029. PMC . PMID 18282093.
- Partidos CD, Weger J, Brewoo J, Seymour R, Borland EM, Ledermann JP, Powers AM, Weaver SC, Stinchcomb DT, Osorio JE (April 2011). "Probing the attenuation and protective efficacy of a candidate chikungunya virus vaccine in mice with compromised interferon (IFN) signaling". Vaccine. 29 (16): 3067–73. doi:10.1016/j.vaccine.2011.01.076. PMC . PMID 21300099.
- White LK, Sali T, Alvarado D, Gatti E, Pierre P, Streblow D, Defilippis VR (January 2011). "Chikungunya virus induces IPS-1-dependent innate immune activation and protein kinase R-independent translational shutoff". J. Virol. 85 (1): 606–20. doi:10.1128/JVI.00767-10. PMC . PMID 20962078.
- Rudd PA, Wilson J, Gardner J, Larcher T, Babarit C, Le TT, Anraku I, Kumagai Y, Loo YM, Gale M, Akira S, Khromykh AA, Suhrbier A (September 2012). "Interferon response factors 3 and 7 protect against Chikungunya virus hemorrhagic fever and shock". J. Virol. 86 (18): 9888–98. doi:10.1128/JVI.00956-12. PMC . PMID 22761364.
- Schilte C, Buckwalter MR, Laird ME, Diamond MS, Schwartz O, Albert ML (April 2012). "Cutting edge: independent roles for IRF-3 and IRF-7 in hematopoietic and nonhematopoietic cells during host response to Chikungunya infection". J. Immunol. 188 (7): 2967–71. doi:10.4049/jimmunol.1103185. PMID 22371392.
- Akhrymuk I, Kulemzin SV, Frolova EI (July 2012). "Evasion of the innate immune response: the Old World alphavirus nsP2 protein induces rapid degradation of Rpb1, a catalytic subunit of RNA polymerase II". J. Virol. 86 (13): 7180–91. doi:10.1128/JVI.00541-12. PMC . PMID 22514352.
- Fros JJ, Liu WJ, Prow NA, Geertsema C, Ligtenberg M, Vanlandingham DL, Schnettler E, Vlak JM, Suhrbier A, Khromykh AA, Pijlman GP (October 2010). "Chikungunya virus nonstructural protein 2 inhibits type I/II interferon-stimulated JAK-STAT signaling". J. Virol. 84 (20): 10877–87. doi:10.1128/JVI.00949-10. PMC . PMID 20686047.
- Voss, JE; Vaney, MC; Duquerroy, S; Vonrhein, C; Girard-Blanc, C; Crublet, E; Thompson, A; Bricogne, G; Rey, FA (2 December 2010). "Glycoprotein organization of Chikungunya virus particles revealed by X-ray crystallography.". Nature. 468 (7324): 709–12. doi:10.1038/nature09555. PMID 21124458.
- "Chikungunya Virus Infections". New England Journal of Medicine. 373: 93–95. doi:10.1056/NEJMc1505501.
- Morens DM and Fauci AS (4 September 2014). "Chikungunya at the Door—Déjà Vu All Over Again?". New England Journal of Medicine. 371 (10): 885–887. doi:10.1056/NEJMp1408509. PMID 25029435. Retrieved 12 September 2014.
- "Laboratory Diagnosis of Chikungunya Fevers". World Health Organization. Archived from the original on 8 September 2012. Retrieved 20 May 2013.
- Schilte, C; Staikowsky, F; Couderc, T; Madec, Y; Carpentier, F; Kassab, S; Albert, ML; Lecuit, M; Michault, A (2013). "Chikungunya virus-associated long-term arthralgia: a 36-month prospective longitudinal study.". PLoS neglected tropical diseases. 7 (3): e2137. doi:10.1371/journal.pntd.0002137. PMID 23556021.
- Edelman R, Tacket CO, Wasserman SS, Bodison SA, Perry JG, Mangiafico JA (June 2000). "Phase II safety and immunogenicity study of live chikungunya virus vaccine TSI-GSD-218". Am. J. Trop. Med. Hyg. 62 (6): 681–5. PMID 11304054.
- Gorchakov R, Wang E, Leal G, Forrester NL, Plante K, Rossi SL, Partidos CD, Adams AP, Seymour RL, Weger J, Borland EM, Sherman MB, Powers AM, Osorio JE, Weaver SC (June 2012). "Attenuation of Chikungunya virus vaccine strain 181/clone 25 is determined by two amino acid substitutions in the E2 envelope glycoprotein.". Journal of Virology. 86 (11): 6084–96. doi:10.1128/JVI.06449-11. PMID 22457519.
- Plante K, Wang E, Partidos CD, Weger J, Gorchakov R, Tsetsarkin K, Borland EM, Powers AM, Seymour R, Stinchcomb DT, Osorio JE, Frolov I, Weaver SC (Jul 2011). "Novel chikungunya vaccine candidate with an IRES-based attenuation and host range alteration mechanism.". PLoS Pathogens. 7 (7): e1002142. doi:10.1371/journal.ppat.1002142. PMID 21829348.
- Hallengärd D, Kakoulidou M, Lulla A, Kümmerer BM, Johansson DX, Mutso M, Lulla V, Fazakerley JK, Roques P, Le Grand R, Merits A, Liljeström P (26 December 2013). "Novel attenuated Chikungunya vaccine candidates elicit protective immunity in C57BL/6 mice.". Journal of Virology. 88 (5): 2858–66. doi:10.1128/JVI.03453-13. PMID 24371047.
- "Experimental chikungunya vaccine passes first test". NPR. 15 August 2014. Retrieved 15 August 2014.
- Al Idrus, Amirah (2 December 2015). "NIAID to bring Chikungunya vaccine into Phase II". fiercevaccines.com. Retrieved 24 March 2016.
- Morens DM, Fauci AS (4 September 2014). "Chikungunya at the door--déjà vu all over again?". The New England Journal of Medicine. 371 (10): 885–7. doi:10.1056/nejmp1408509. PMID 25029435.
- "Chikungunya—Fact sheet". European Centre for Disease Prevention and Control (ECDC). Retrieved 2013-12-17.
- Couderc, T; Khandoudi, N; Grandadam, M; Visse, C; Gangneux, N; Bagot, S; Prost, JF; Lecuit, M (15 August 2009). "Prophylaxis and therapy for Chikungunya virus infection.". The Journal of Infectious Diseases. 200 (4): 516–23. doi:10.1086/600381. PMID 19572805.
- Mavalankar D, Shastri P, Bandyopadhyay T, Parmar J, Ramani KV (2008). "Increased Mortality Rate Associated with Chikungunya Epidemic, Ahmedabad, India". Emerging Infectious Diseases. 14 (3): 412–5. doi:10.3201/eid1403.070720. PMC . PMID 18325255.
- Seppa, Nathan (2 Jun 2015). "Chikungunya is on the move". Science News. Retrieved 13 June 2015.
- Poh, Lisa Ng Fong; Sam, I-Ching; Loong, Shih-Keng; Michael, Jasmine Chandramathi; Chua, Chong-Long; Wan Sulaiman, Wan Yusoff; Vythilingam, Indra; Chan, Shie-Yien; Chiam, Chun-Wei; Yeong, Yze-Shiuan; AbuBakar, Sazaly; Chan, Yoke-Fun (2012). "Genotypic and Phenotypic Characterization of Chikungunya Virus of Different Genotypes from Malaysia". PLoS ONE. 7 (11): e50476. doi:10.1371/journal.pone.0050476. ISSN 1932-6203.
- Lahariya C, Pradhan SK (December 2006). "Emergence of chikungunya virus in Indian subcontinent after 32 years: A review" (PDF). J Vector Borne Dis. 43 (4): 151–60. PMID 17175699.
- Roth, Adam; Hoy, Damian; Horwood, Paul F.; Ropa, Berry; Hancock, Thane; Guillaumot, Laurent; Rickart, Keith; Frison, Pascal; Pavlin, Boris; Souares, Yvan (2014). "Preparedness for Threat of Chikungunya in the Pacific". Emerging Infectious Diseases. 20 (8). doi:10.3201/eid2008.130696. ISSN 1080-6040.
- Muniaraj M (2014). "Fading chikungunya fever from India: beginning of the end of another episode?". Indian J. Med. Res. 139 (3): 468–70. PMC . PMID 24820844.
- "Number of cumulative cases 2013-2014". http://www.paho.org. Pan-American Health Organization (PAHO). 15 May 2015. Retrieved 19 July 2015. External link in
- Schuffenecker I, Iteman I, Michault A, et al. (July 2006). "Genome microevolution of chikungunya viruses causing the Indian Ocean outbreak". PLoS Med. 3 (7): e263. doi:10.1371/journal.pmed.0030263. PMC . PMID 16700631.
- Tsetsarkin KA, Vanlandingham DL, McGee CE, Higgs S (2007). "A Single Mutation in Chikungunya Virus Affects Vector Specificity and Epidemic Potential". PLoS Pathog. 3 (12): e201. doi:10.1371/journal.ppat.0030201. PMC . PMID 18069894.
- Liumbruno GM, Calteri D, Petropulacos K, et al. (2008). "The Chikungunya epidemic in Italy and its repercussion on the blood system". Blood Transfusion = Trasfusione Del Sangue. 6 (4): 199–210. doi:10.2450/2008.0016-08 (inactive 2016-08-01). PMC . PMID 19112735.
- Centers for Disease Control Prevention (CDC) (29 September 2006). "Chikungunya fever diagnosed among international travelers—United States, 2005–2006". MMWR Morb. Mortal. Wkly. Rep. 55 (38): 1040–2. PMID 17008866.
- Robinson MC (1955). "An epidemic of virus disease in Southern Province, Tanganyika Territory, in 1952-53. I. Clinical features". Trans. R. Soc. Trop. Med. Hyg. 49 (1): 28–32. doi:10.1016/0035-9203(55)90080-8. PMID 14373834.
- Lumsden WH (1955). "An epidemic of virus disease in Southern Province, Tanganyika Territory, in 1952–53. II. General description and epidemiology". Trans. R. Soc. Trop. Med. Hyg. 49 (1): 33–57. doi:10.1016/0035-9203(55)90081-X. PMID 14373835.
- Benjamin M (2008). "Chikungunya is NOT a Swahili word, it is from the Makonde language!".
- Carey DE (July 1971). "Chikungunya and dengue: a case of mistaken identity?". J Hist Med Allied Sci. 26 (3): 243–62. doi:10.1093/jhmas/XXVI.3.243. PMID 4938938.
- Cherian SS, Walimbe AM, Jadhav SM, Gandhe SS, Hundekar SL, Mishra AC, Arankalle VA (January 2009). "Evolutionary rates and timescale comparison of Chikungunya viruses inferred from the whole genome/E1 gene with special reference to the 2005-07 outbreak in the Indian subcontinent". Infect. Genet. Evol. 9 (1): 16–23. doi:10.1016/j.meegid.2008.09.004. PMID 18940268.
- "Chemical and Biological Weapons: Possession and Programs Past and Present", James Martin Center for Nonproliferation Studies, Middlebury College, 9 April 2002, accessed 18 June 2014.
- http://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0001892 Impact of Wolbachia on Infection with Chikungunya and Yellow Fever Viruses in the Mosquito Vector Aedes aegypti
- http://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0004677 The wMel Strain of Wolbachia Reduces Transmission of Chikungunya Virus in Aedes aegypti
- "Neglected tropical diseases". WHO. Retrieved 26 September 2016.